香港 (CH) 病理檢驗中心 很高興能夠向你提供 COVID-19 RT-PCR 新冠病毒核酸測試。

我們是香港特區政府認可的 COVID-19 RT-PCR新冠病毒核酸檢測實驗室之一:

(https://www.coronavirus.gov.hk/pdf/List_of_recognised_laboratories.pdf)

Update: 30-Sep-2020

「常規」和「特快」之 COVID-19 RT-PCR 新冠病毒核酸測試:

*必須預先取得註冊醫生作此項測試的轉介信。*
請注意：化驗報告如作「航空旅遊氣泡」除外的離境用途時，請先自行向該海關查證對 - 採取樣本時間或發出化驗報告時間的要求，以確定化驗報告於有效期內應用。

測試費用及報告發出需要時間：

• 例行測試: HK$800
  (樣本必須當日下午4時前交到巳選擇的中心, 翌日下午3時 後請取回化驗報告。)
• 特快測試: HK$1,000
  (樣本必須當日早上10時前交到巳選擇的中心, 即日下午5時 後請取回化驗報告。)

測試標本為深喉唾液

檢測報告內容會包含以下資料:
- 姓名
- 證件號碼
- 出生日期 / 年齡
- 性別
- 測試結果
- 接收測試樣品的日期
- 標本編號
- 測試提供機構名稱
- 測試方式的名稱 (RT-PCR)

 程序：
1）先取得醫生轉介信
2）再來電預約：

• 中環 ：2522-1860
• 佐敦 ：2782-1096
• 沙田：2602-5015

3）預約後，須提前1天到所選擇中心領取收集標本採集套件，預計早上在家中收集樣本。
4）早上起床後，在刷牙和進食之前，請按程序自行收集深喉唾液樣本於樣本瓶中。
5）將樣本送回所選擇分行。標本必須用雙層袋裝，並在外部標本袋的袋鼠袋中放入 醫生轉介信 。 同時 請攜帶你的身份證明文件，例如香港身份證，護照或其他旅行證件…並繳交費用。

*根據法規，如新冠病毒核酸測試結果為陽性，樣本必須送交衛生署再確認及跟進處理。

Update: 10-Jun-2020

New in-house test : Prostate Health Index (PHI 前列腺健康指數組合)

Prostate cancer is the fourth leading cause of male cancer in Hong Kong and the incidence is increasing at the fastest rate among all cancers affecting men. Although total Prostate-Specific Antigen (PSA) test is widely used as a screening tool for prostate cancer, its level will also be affected by benign prostatic conditions (e.g. benign prostatic hyperplasia, prostatitis) and often leads to unnecessary prostate biopsies.

Prostate Health Index (PHI) is a score calculated from the 3 PSA isoforms {PSA, free PSA, p2PSA}. The higher the PHI score, the higher probability of finding clinically-significant prostate cancer upon prostate biopsy. This test has the following advantages:

• In 2012, the US Food and Drug Administration (FDA) has approved PHI as a screening tool of prostate cancer in men above 50 years old with a PSA level of 2 - 10 ng/mL and normal DRE.

• Local studies have shown that PHI is a good predictor of prostate biopsy outcome. With a better sensitivity and specificity, PHI is useful to avoid over 40% of unnecessary prostate biopsies in patients with PSA level of 2 – 10 ng/mL. (#)

• PHI is not only a useful predictor of prostate biopsy outcome, it also identifies high-grade disease, predict adverse treatment outcome as well as aid to select the right candidate for active disease surveillance. It offers a better risk stratification and helps clinicians with a better clinical management of their patients. (&)

# Ng CF et al. (2014) The Prostate Health Index in predicting initial prostate biopsy outcomes in Asian men with prostate-specific antigen levels of 4-10 ng/mL. Int Urol Nephrol

^ Chiu PK, Ng CF et al. (2018) A multi-centre evaluation of the role of Prostate Health Index (PHI) in regions with different prevalences of prostate cancer: A different reference range is needed for European and Asian. European Urology Supplements

& Lepor A et al. (2016) The Prostate Health Index : Its Utility In Prostate Cancer Detection. Urol Clin North Am.

Update: 29-Jan-2020
*Click here to visit FluTest.hk by Roche*